#United States #Boulder #Biopharmaceutical #Common Stock #Enliven Therapeutics

Enliven Therapeutics' Recent Public Offering

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical enterprise specializing in small molecule therapeutics, recently made headlines with the announcement of its public offering. On June 13, 2025, the Boulder, Colorado-based company revealed that it had priced its previously announced underwritten public offering of 8,394,737 shares of common stock at a price of $19.66 per share.

In addition, the company also introduced pre-funded warrants intended for investors who opt for this alternative. These allow the purchase of up to 1,780,263 shares of Enliven's common stock at a pricing model of $19.659 per pre-funded warrant, which essentially represents the offering price of the common shares, minus an exercise price of $0.001 per share.

The anticipated gross proceeds from this offering are expected to approach $200 million, which will be calculated before the deduction of underwriting discounts, commissions, and other associated expenses. The completion of this offering is projected to occur on or around June 16, 2025, pending the satisfaction of standard closing conditions.

Adding further dynamics to the offering, Enliven granted the underwriters a 30-day option to purchase up to an additional 1,526,250 shares at the public offering price. This strategy reflects the company's potential market confidence and eagerness to capitalize on investor interest.

The investment banking firms Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho Securities are servicing as joint book-running managers for this offering, while LifeSci Capital takes the lead as the manager. Such reputable firms are expected to draw considerable investor attention, optimizing the likelihood of the offering's success.

This public offering falls under a Registration Statement on Form S-3, which the company had previously submitted and has been declared effective by the SEC. Additionally, a preliminary prospectus supplement, along with an accompanying prospectus, has been filed to provide potential investors with detailed information.

For those interested, these documents can be freely accessed via the SEC's official website at www.sec.gov. When the final prospectus becomes available, copies will be obtainable from the respective underwriters, who have provided their contact information for inquiries regarding the purchase and details of the offering.

It is pertinent to note that this press release does not serve as an offer to sell or a request for any purchase of securities—sales of these shares will be contingent upon registration or qualification under the securities laws of relevant jurisdictions.

Despite recent positive momentum, forward-looking statements made by Enliven carry inherent risks and challenges that could impact the anticipated outcomes, including the efficacy of their capital-raising efforts and the satisfaction of customary conditions for closing the offering.

About Enliven Therapeutics

Enliven Therapeutics is dedicated to discovering and developing innovative small molecule therapeutics that strive to improve the quality of life for patients. With a focus on precision oncology approaches, Enliven aims to address both current and emerging unmet health needs. By harnessing insights into validated biological targets and employing advanced chemistry, the company is positioned to create therapies that can become trailblazing in their fields.

Headquartered in Boulder, Colorado, Enliven Therapeutics continues to pave the way in the biopharmaceutical landscape, ensuring that their initiatives lead to both longer and better lives for individuals in need of medical advancements. The ambition of the company is clear: to revolutionize health outcomes through science, compassion, and commitment. As the biopharmaceutical sector continues to progress, offerings like theirs may play a pivotal role in addressing crucial health challenges.